Rishi Sawhney, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 11
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: San Ramon Regional Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
11 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sawhney’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
11 of 11 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A86449 · Current
Licensed to practise in California · since 2004 · expires 2028-03-31 · University of Mumbai, Grant Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- San Ramon Regional Medical CenterSan Ramon, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 3 of 5 · 65% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for San Ramon Regional Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0 to 1.97) · 507 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.83 (0.44 to 1.22) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.1 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 87 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.2 · 195 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.7 · 284 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 63 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,118 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 2,515 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.08 to 0.49) · 2,618 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.62 (1.26 to 5.98) · 588 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.14) · 282 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.34 (0.72 to 3.97) · 598 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.12 (0.84 to 15.4) · 258 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.08 (0.25 to 7.91) · 225 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.02 (0.52 to 3.52) · 241 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.29) · 2,110 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 73 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.553 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.104 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 84 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 186 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 39.6 · 79 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -10.3 · 227 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.2 · 305 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 314 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.4 to 17.3) · 86 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 256 cases | No different | Jan 2024 – Dec 2024 |
What patients said (642 patients answered, 25% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$838,313
Medicare paid this office $838,313 for 1,082 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 824 | $187,764 | $112 |
| Long return visit (40+ min) | 381 | $132,387 | $164 |
| New patient visit (60+ min) | 147 | $28,906 | $197 |
| Injection, denosumab, 1 mg | 15 | $24,017 | None |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 767 | $18,473 | $15 |
See all 26 services
| Return visit (30+ min) | 824 | $187,764 | $112 |
| Long return visit (40+ min) | 381 | $132,387 | $164 |
| New patient visit (60+ min) | 147 | $28,906 | $197 |
| Injection, denosumab, 1 mg | 15 | $24,017 | None |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 767 | $18,473 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $15,185 | $103 |
| Short return visit (20+ min) | 127 | $11,976 | $86 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13 | $9,276 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $8,560 | None |
| Administration of chemotherapy into vein, 1 hour or less | 34 | $7,196 | $138 |
| New patient visit (45+ min) | 46 | $6,859 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $6,601 | $69 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,246 | $152 |
| Drawing of blood for a medical problem | 17 | $2,685 | $96 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $1,814 | $67 |
| Injection of additional new drug or substance into vein | 31 | $1,661 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $994 | $62 |
| Administration of chemotherapy into vein, each additional hour | 15 | $823 | $28 |
| Irrigation of implanted venous access drug delivery device | 16 | $732 | $25 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 62 | $670 | $8 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $629 | $37 |
| Injection of drug or substance under skin or into muscle | 37 | $620 | $13 |
| Insertion of needle into vein for collection of blood sample | 56 | $528 | $9 |
| Injection, palonosetron hcl, 25 mcg | 22 | $229 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 23 | $35 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 20 | $18 | None |
Who their Medicare patients are
1,082 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 17% · Women 51% · Also on Medicaid 14% · Health risk score 1.79. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 75% · Cancer 42% · Chronic kidney disease 41% · Diabetes 31% · Coronary heart disease 27% · Atrial fibrillation 22% · Heart failure 20% · Depression 19% · COPD 18% · Dementia 9% · Stroke 9%.
The office billed $3,704,652, Medicare allowed $1,080,764 and paid $838,313; for 41,543 services of 90 kinds; $402,151 of it was for drugs given in the office and $436,163 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,082 | 41,543 | 76 | 1.79 | $3,704,652 | $838,313 |
| 2023 | 1,050 | 80,220 | 76 | 1.77 | $5,907,731 | $1,315,925 |
| 2022 | 1,075 | 114,592 | 76 | 1.82 | $6,951,848 | $1,561,119 |
| 2021 | 1,032 | 261,462 | 76 | 1.88 | $12,278,852 | $2,811,443 |
| 2020 | 992 | 274,674 | 75 | 1.97 | $18,620,070 | $4,138,494 |
| 2019 | 1,052 | 320,925 | 75 | 1.96 | $14,683,387 | $3,447,437 |
| 2018 | 927 | 370,602 | 75 | 1.95 | $13,508,607 | $3,147,428 |
| 2017 | 870 | 372,025 | 75 | 1.89 | $12,513,983 | $2,943,450 |
| 2016 | 848 | 528,802 | 75 | 1.88 | $10,911,809 | $3,302,104 |
| 2015 | 799 | 442,304 | 75 | 1.90 | $11,721,331 | $3,823,528 |
| 2014 | 933 | 433,446 | 75 | 1.79 | $11,161,867 | $3,525,597 |
| 2013 | 658 | 225,727 | 75 | 1.84 | $7,635,325 | $2,594,343 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 34 services
| Return visit (30+ min) | 809 | $177,762 | $109 |
| Injection, pembrolizumab, 1 mg | 13 | $130,254 | None |
| Long return visit (40+ min) | 355 | $110,947 | $161 |
| Injection, denosumab, 1 mg | 28 | $70,615 | None |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 20 | $48,943 | None |
| New patient visit (60+ min) | 157 | $30,486 | $194 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 18 | $18,270 | None |
| Administration of chemotherapy into vein, 1 hour or less | 53 | $16,478 | $138 |
| Injection, ferric carboxymaltose, 1 mg | 13 | $11,261 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $10,969 | $105 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $8,418 | None |
| Drawing of blood for a medical problem | 29 | $7,728 | $93 |
| New patient visit (45+ min) | 54 | $7,666 | $142 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 41 | $4,114 | $64 |
| Short return visit (20+ min) | 48 | $4,090 | $74 |
| Injection of additional new drug or substance into vein | 47 | $4,070 | $16 |
| Administration of additional new drug or substance into vein, 1 hour or less | 29 | $3,644 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $3,367 | $70 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 186 | $3,227 | $8 |
| Injection of drug or substance under skin or into muscle | 92 | $2,520 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,306 | $154 |
| Administration of chemotherapy into vein, each additional hour | 20 | $1,980 | $29 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $1,431 | $35 |
| Irrigation of implanted venous access drug delivery device | 17 | $1,414 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 16 | $979 | $30 |
| Injection of drug or substance into vein | 22 | $943 | $38 |
| Injection, zoledronic acid, 1 mg | 23 | $914 | None |
| Application of on-body injector for under skin injection | 19 | $833 | $19 |
| Injection, palonosetron hcl, 25 mcg | 36 | $640 | None |
| Injection, fosaprepitant, 1 mg | 14 | $597 | None |
| Infusion into a vein for hydration, each additional hour | 12 | $336 | $13 |
| Injection, carboplatin, 50 mg | 11 | $259 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 37 | $95 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 38 | $70 | None |
2022: 44 services
| Return visit (30+ min) | 812 | $195,008 | $110 |
| Injection, pembrolizumab, 1 mg | 13 | $176,430 | None |
| Injection, denosumab, 1 mg | 38 | $100,614 | None |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 25 | $71,763 | None |
| Long return visit (40+ min) | 243 | $69,470 | $164 |
| Administration of chemotherapy into vein, 1 hour or less | 79 | $37,581 | $142 |
| New patient visit (60+ min) | 148 | $29,942 | $202 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 20 | $23,717 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 23 | $21,121 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 26 | $15,133 | $1 |
| New patient visit (45+ min) | 106 | $15,120 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $13,776 | $91 |
| Short return visit (20+ min) | 117 | $11,975 | $77 |
| Drawing of blood for a medical problem | 26 | $8,915 | $102 |
| Injection of additional new drug or substance into vein | 75 | $8,802 | $16 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 14 | $8,618 | $172 |
| Administration of additional new drug or substance into vein, 1 hour or less | 37 | $7,477 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 55 | $5,697 | $67 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 223 | $4,432 | $8 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,201 | $175 |
| Administration of chemotherapy into vein, each additional hour | 26 | $4,194 | $30 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $3,689 | $77 |
| Injection of drug or substance under skin or into muscle | 113 | $3,600 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $3,535 | $63 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $2,649 | $34 |
| Administration of additional new drug or substance into vein using push technique | 20 | $2,325 | $60 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 18 | $2,059 | None |
| Irrigation of implanted venous access drug delivery device | 31 | $1,991 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 23 | $1,717 | $31 |
| Injection of drug or substance into vein | 28 | $1,463 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 16 | $1,433 | $21 |
| Application of on-body injector for under skin injection | 25 | $1,420 | $19 |
| Injection, palonosetron hcl, 25 mcg | 48 | $1,277 | None |
| Insertion of needle into vein for collection of blood sample | 169 | $1,161 | $3 |
| Injection, fosaprepitant, 1 mg | 19 | $956 | None |
| Injection, zoledronic acid, 1 mg | 23 | $766 | None |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $736 | $35 |
| Injection, fluorouracil, 500 mg | 14 | $665 | None |
| Injection, carboplatin, 50 mg | 12 | $483 | None |
| Infusion into a vein for hydration, each additional hour | 16 | $376 | $13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 53 | $175 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 42 | $107 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 17 | $35 | None |
| Infusion, normal saline solution , 1000 cc | 11 | $32 | None |
2021: 54 services
| Injection, pembrolizumab, 1 mg | 22 | $269,394 | None |
| Injection, denosumab, 1 mg | 55 | $218,188 | None |
| Return visit (30+ min) | 750 | $215,705 | $116 |
| Injection, rituximab, 10 mg | 11 | $110,191 | None |
| Injection, pegfilgrastim, 6 mg | 17 | $96,251 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 38 | $82,711 | None |
| Administration of chemotherapy into vein, 1 hour or less | 107 | $72,365 | $154 |
| Long return visit (40+ min) | 215 | $63,112 | $166 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 41 | $32,743 | $1 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 87 | $25,963 | $94 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 28 | $25,632 | None |
| New patient visit (60+ min) | 102 | $21,458 | $210 |
| Short return visit (20+ min) | 142 | $19,340 | $82 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 20 | $18,854 | $178 |
| Injection of additional new drug or substance into vein | 103 | $16,173 | $17 |
| New patient visit (45+ min) | 88 | $13,444 | $153 |
| Administration of additional new drug or substance into vein, 1 hour or less | 50 | $12,840 | $75 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $10,852 | $86 |
| Injection, ferric carboxymaltose, 1 mg | 12 | $10,071 | None |
| Drawing of blood for a medical problem | 23 | $9,671 | $109 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 67 | $9,655 | $75 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 315 | $8,104 | $8 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $7,496 | $65 |
| Injection of drug or substance under skin or into muscle | 156 | $7,297 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,085 | $182 |
| Telephone medical discussion with physician, 11-20 minutes | 94 | $7,079 | $64 |
| Administration of additional new drug or substance into vein using push technique | 20 | $5,944 | $65 |
| Administration of chemotherapy into vein, each additional hour | 40 | $5,223 | $32 |
| Injection, palonosetron hcl, 25 mcg | 62 | $4,502 | None |
| Irrigation of implanted venous access drug delivery device | 35 | $4,296 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 33 | $3,737 | $33 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 38 | $3,543 | $32 |
| Insertion of needle into vein for collection of blood sample | 356 | $3,330 | $3 |
| Injection, fosaprepitant, 1 mg | 24 | $3,215 | None |
| Injection of drug or substance into vein | 41 | $2,561 | $41 |
| Injection, oxaliplatin, 0.5 mg | 19 | $2,177 | None |
| Infusion into a vein for hydration, 31-60 minutes | 32 | $1,947 | $37 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,716 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $1,647 | $23 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $1,547 | None |
| Injection, fluorouracil, 500 mg | 20 | $1,410 | None |
| Infusion into a vein for hydration, each additional hour | 37 | $1,134 | $14 |
| Injection, zoledronic acid, 1 mg | 20 | $955 | None |
| Injection, paclitaxel, 1 mg | 12 | $702 | None |
| Application of on-body injector for under skin injection | 15 | $693 | $20 |
| Injection, carboplatin, 50 mg | 20 | $631 | None |
| Telephone medical discussion with physician, 5-10 minutes | 11 | $470 | $43 |
| Injection, dexamethasone sodium phosphate, 1 mg | 74 | $381 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 62 | $178 | None |
| Infusion, normal saline solution , 1000 cc | 33 | $141 | None |
| Automated urinalysis test | 14 | $113 | $2 |
| Injection, ondansetron hydrochloride, per 1 mg | 23 | $60 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 17 | $36 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $29 | None |
2020: 54 services
| Injection, pembrolizumab, 1 mg | 21 | $891,858 | None |
| Injection, denosumab, 1 mg | 70 | $265,559 | None |
| Injection, rituximab, 10 mg | 19 | $246,057 | None |
| Injection, pegfilgrastim, 6 mg | 29 | $171,329 | None |
| Return visit (30+ min) | 644 | $137,570 | $95 |
| Injection, paclitaxel protein-bound particles, 1 mg | 11 | $119,919 | None |
| Administration of chemotherapy into vein, 1 hour or less | 130 | $94,734 | $146 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 37 | $86,272 | None |
| Long return visit (40+ min) | 214 | $49,015 | $135 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 26 | $30,437 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 93 | $26,452 | $95 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 30 | $25,699 | $1 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 20 | $24,554 | None |
| New patient visit (60+ min) | 124 | $22,663 | $183 |
| Injection of additional new drug or substance into vein | 117 | $20,514 | $16 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 19 | $19,023 | $170 |
| Administration of additional new drug or substance into vein, 1 hour or less | 59 | $16,664 | $72 |
| Telephone medical discussion with physician, 11-20 minutes | 165 | $14,460 | $70 |
| Injection, fosaprepitant, 1 mg | 30 | $11,934 | None |
| Injection, palonosetron hcl, 25 mcg | 81 | $11,846 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 411 | $10,030 | $8 |
| Short return visit (20+ min) | 85 | $8,865 | $67 |
| New patient visit (45+ min) | 61 | $8,702 | $143 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 48 | $7,923 | $71 |
| Injection of drug or substance under skin or into muscle | 177 | $7,816 | $13 |
| Administration of chemotherapy into vein using push technique | 17 | $7,804 | $111 |
| Administration of additional new drug or substance into vein using push technique | 32 | $7,298 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $7,035 | $185 |
| Drawing of blood for a medical problem | 18 | $6,849 | $99 |
| Administration of chemotherapy into vein, each additional hour | 46 | $6,141 | $31 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $5,208 | $66 |
| Irrigation of implanted venous access drug delivery device | 52 | $4,950 | $28 |
| Insertion of needle into vein for collection of blood sample | 461 | $4,121 | $3 |
| Telephone medical discussion with physician, 21-30 minutes | 32 | $3,502 | $100 |
| Injection of drug or substance into vein | 42 | $3,082 | $41 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $2,800 | $30 |
| Infusion into a vein for hydration, 31-60 minutes | 34 | $2,717 | $35 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 34 | $2,475 | $31 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 22 | $2,256 | None |
| Injection, docetaxel, 1 mg | 13 | $1,992 | None |
| Injection, oxaliplatin, 0.5 mg | 17 | $1,652 | None |
| Telephone medical discussion with physician, 5-10 minutes | 30 | $1,463 | $43 |
| Injection, fluorouracil, 500 mg | 20 | $1,383 | None |
| Infusion into a vein for hydration, each additional hour | 21 | $1,363 | $14 |
| Injection, zoledronic acid, 1 mg | 22 | $1,217 | None |
| Injection, carboplatin, 50 mg | 22 | $1,116 | None |
| Application of on-body injector for under skin injection | 24 | $866 | $20 |
| Injection, paclitaxel, 1 mg | 13 | $715 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 97 | $388 | None |
| Infusion, normal saline solution , 1000 cc | 35 | $203 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 74 | $190 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 20 | $85 | None |
| Automated urinalysis test | 12 | $80 | $2 |
| Injection, ondansetron hydrochloride, per 1 mg | 24 | $58 | None |
2019: 55 services
| Injection, pembrolizumab, 1 mg | 21 | $796,497 | None |
| Injection, rituximab, 10 mg | 22 | $325,194 | None |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 12 | $273,520 | None |
| Injection, denosumab, 1 mg | 63 | $242,216 | None |
| Return visit (30+ min) | 743 | $172,251 | $96 |
| Injection, pegfilgrastim, 6 mg | 14 | $158,155 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 35 | $136,807 | None |
| Administration of chemotherapy into vein, 1 hour or less | 116 | $70,997 | $145 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 27 | $42,937 | None |
| Long return visit (40+ min) | 161 | $35,582 | $135 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 43 | $27,029 | $1 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 90 | $26,239 | $94 |
| Short return visit (20+ min) | 160 | $20,538 | $66 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $20,521 | None |
| New patient visit (60+ min) | 104 | $19,791 | $190 |
| Injection, ferric carboxymaltose, 1 mg | 22 | $18,431 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 712 | $17,124 | $8 |
| Injection, palonosetron hcl, 25 mcg | 56 | $16,577 | None |
| Injection of additional new drug or substance into vein | 104 | $13,363 | $17 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 11 | $13,153 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 49 | $13,146 | $71 |
| New patient visit (45+ min) | 75 | $10,280 | $137 |
| Injection, fosaprepitant, 1 mg | 14 | $10,057 | None |
| Injection of drug or substance under skin or into muscle | 167 | $9,595 | $16 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $8,935 | $182 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 14 | $8,492 | $163 |
| Administration of chemotherapy into vein, each additional hour | 49 | $7,233 | $31 |
| Administration of additional new drug or substance into vein using push technique | 29 | $6,607 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $5,771 | $66 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 57 | $5,512 | $31 |
| Infusion into a vein for hydration, 31-60 minutes | 36 | $5,470 | $39 |
| Injection of drug or substance into vein | 81 | $4,977 | $40 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $4,929 | $82 |
| Administration of chemotherapy into vein using push technique | 12 | $4,923 | $112 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 13 | $4,322 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 37 | $4,022 | $74 |
| Irrigation of implanted venous access drug delivery device | 44 | $3,361 | $27 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 34 | $2,556 | $29 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,460 | $123 |
| Insertion of needle into vein for collection of blood sample | 450 | $2,390 | $3 |
| Injection, oxaliplatin, 0.5 mg | 16 | $1,915 | None |
| Drawing of blood for a medical problem | 12 | $1,720 | $101 |
| Injection, zoledronic acid, 1 mg | 20 | $1,385 | None |
| Injection, fluorouracil, 500 mg | 20 | $1,198 | None |
| Injection, carboplatin, 50 mg | 20 | $1,189 | None |
| Infusion into a vein for hydration, each additional hour | 19 | $1,114 | $14 |
| Injection, ranitidine hydrochloride, 25 mg | 42 | $976 | None |
| Injection, paclitaxel, 1 mg | 14 | $761 | None |
| Application of on-body injector for under skin injection | 14 | $628 | $20 |
| Injection, dexamethasone sodium phosphate, 1 mg | 87 | $319 | None |
| Infusion, normal saline solution , 1000 cc | 36 | $305 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 13 | $134 | $7 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 28 | $116 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 69 | $116 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 20 | $40 | None |
2018: 56 services
| Injection, denosumab, 1 mg | 66 | $259,910 | None |
| Injection, rituximab, 100 mg | 13 | $245,986 | None |
| Return visit (30+ min) | 735 | $213,024 | $91 |
| Injection, pegfilgrastim, 6 mg | 22 | $212,152 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 40 | $199,130 | None |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 27 | $65,524 | None |
| Administration of chemotherapy into vein, 1 hour or less | 92 | $60,505 | $141 |
| Injection, ferric carboxymaltose, 1 mg | 43 | $39,787 | None |
| Injection, palonosetron hcl, 25 mcg | 51 | $36,604 | None |
| Long return visit (40+ min) | 171 | $35,957 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 107 | $25,883 | $90 |
| Short return visit (20+ min) | 174 | $25,670 | $62 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 718 | $22,443 | $9 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $18,884 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 13 | $16,423 | None |
| New patient visit (60+ min) | 85 | $15,324 | $180 |
| Injection of drug or substance under skin or into muscle | 166 | $14,219 | $19 |
| Administration of additional new drug or substance into vein using push technique | 29 | $11,446 | $58 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 19 | $11,235 | None |
| Injection of additional new drug or substance into vein | 84 | $11,211 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 64 | $10,986 | $172 |
| Administration of prolonged chemotherapy into vein | 12 | $10,048 | $144 |
| New patient visit (45+ min) | 66 | $9,372 | $142 |
| Administration of additional new drug or substance into vein, 1 hour or less | 36 | $8,583 | $68 |
| Injection, fosaprepitant, 1 mg | 12 | $8,538 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 65 | $8,105 | $30 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $7,654 | $63 |
| Administration of chemotherapy into vein, each additional hour | 44 | $6,961 | $30 |
| Infusion into a vein for hydration, 31-60 minutes | 41 | $6,873 | $46 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 22 | $5,567 | $72 |
| Injection of drug or substance into vein | 64 | $4,855 | $46 |
| Irrigation of implanted venous access drug delivery device | 34 | $3,720 | $26 |
| Injection, oxaliplatin, 0.5 mg | 18 | $3,581 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $2,868 | $80 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,698 | $117 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $2,611 | $27 |
| Drawing of blood for a medical problem | 11 | $1,990 | $100 |
| Aspiration of bone marrow sample for diagnosis | 12 | $1,955 | $163 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $1,738 | None |
| Injection, fluorouracil, 500 mg | 19 | $1,731 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $1,495 | $21 |
| Injection, zoledronic acid, 1 mg | 16 | $1,364 | None |
| Application of on-body injector for under skin injection | 20 | $1,021 | $20 |
| Injection, carboplatin, 50 mg | 20 | $1,007 | None |
| Injection, ranitidine hydrochloride, 25 mg | 39 | $816 | None |
| Biopsy of bone marrow | 11 | $809 | $74 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $780 | $20 |
| Infusion into a vein for hydration, each additional hour | 25 | $691 | $13 |
| Injection, paclitaxel, 1 mg | 15 | $501 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 71 | $296 | None |
| Infusion, normal saline solution , 1000 cc | 36 | $216 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 26 | $174 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 49 | $91 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 17 | $31 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 13 | $25 | None |
| Not otherwise classified, antineoplastic drugs | 14 | $20 | None |
2017: 46 services
| Injection, denosumab, 1 mg | 62 | $302,051 | None |
| Return visit (30+ min) | 718 | $225,098 | $94 |
| Injection, rituximab, 100 mg | 12 | $189,208 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 31 | $149,269 | None |
| Injection, pegfilgrastim, 6 mg | 16 | $139,436 | None |
| Injection, ferric carboxymaltose, 1 mg | 53 | $79,121 | None |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 25 | $75,006 | None |
| Administration of chemotherapy into vein, 1 hour or less | 69 | $44,326 | $137 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 124 | $33,051 | $91 |
| Short return visit (20+ min) | 190 | $29,722 | $66 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $28,587 | None |
| Long return visit (40+ min) | 146 | $28,118 | $131 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 677 | $26,988 | $10 |
| Injection, palonosetron hcl, 25 mcg | 37 | $24,505 | None |
| New patient visit (60+ min) | 114 | $20,875 | $183 |
| Injection of drug or substance under skin or into muscle | 157 | $20,512 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 67 | $16,812 | $30 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $11,155 | $177 |
| Infusion into a vein for hydration, 31-60 minutes | 30 | $11,107 | $57 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $10,120 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 68 | $9,994 | $63 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 33 | $9,338 | $69 |
| Injection of drug or substance into vein | 71 | $8,928 | $56 |
| New patient visit (45+ min) | 59 | $8,246 | $140 |
| Administration of additional new drug or substance into vein using push technique | 19 | $4,944 | $62 |
| Administration of chemotherapy into vein, each additional hour | 32 | $4,826 | $27 |
| Injection of additional new drug or substance into vein | 58 | $4,608 | $22 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $4,590 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $3,935 | $119 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $2,574 | $32 |
| Irrigation of implanted venous access drug delivery device | 33 | $2,507 | $23 |
| Aspiration of bone marrow sample for diagnosis | 15 | $2,390 | $159 |
| Injection, zoledronic acid, 1 mg | 15 | $2,023 | None |
| Infusion into a vein for hydration, each additional hour | 23 | $1,988 | $15 |
| Biopsy of bone marrow | 15 | $1,220 | $81 |
| Injection, carboplatin, 50 mg | 13 | $753 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $574 | $20 |
| Insertion of needle into vein for collection of blood sample | 137 | $453 | $3 |
| Infusion, normal saline solution , 1000 cc | 27 | $319 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 25 | $306 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 56 | $247 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 51 | $130 | None |
| Not otherwise classified, antineoplastic drugs | 39 | $76 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 18 | $49 | None |
| Stool analysis for blood to screen for colon tumors | 11 | $48 | $4 |
| Injection, ondansetron hydrochloride, per 1 mg | 17 | $33 | None |
2016: 50 services
| Injection, denosumab, 1 mg | 56 | $297,287 | None |
| Return visit (30+ min) | 712 | $281,262 | $91 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 29 | $276,377 | None |
| Injection, bortezomib, 0.1 mg | 11 | $206,886 | None |
| Injection, pegfilgrastim, 6 mg | 18 | $205,752 | None |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 26 | $103,821 | None |
| Not otherwise classified, antineoplastic drugs | 16 | $103,099 | None |
| Administration of chemotherapy into vein, 1 hour or less | 71 | $74,776 | $130 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 23 | $60,100 | None |
| Injection, palonosetron hcl, 25 mcg | 44 | $51,871 | None |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 11 | $47,302 | None |
| Short return visit (20+ min) | 185 | $45,866 | $63 |
| Injection, ferric carboxymaltose, 1 mg | 32 | $42,156 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 39 | $39,388 | $1 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 648 | $36,043 | $10 |
| Long return visit (40+ min) | 177 | $33,343 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 122 | $32,504 | $89 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 78 | $29,008 | $29 |
| Injection of drug or substance under skin or into muscle | 148 | $26,605 | $24 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 69 | $26,421 | $72 |
| New patient visit (60+ min) | 153 | $26,009 | $170 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 102 | $21,776 | $173 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 79 | $17,126 | $66 |
| Infusion into a vein for hydration, 31-60 minutes | 52 | $14,718 | $55 |
| Administration of additional new drug or substance into vein, 1 hour or less | 31 | $11,819 | $59 |
| Injection, docetaxel, 1 mg | 12 | $10,009 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 65 | $7,998 | $60 |
| Administration of additional new drug or substance into vein using push technique | 15 | $7,131 | $60 |
| Injection, oxaliplatin, 0.5 mg | 12 | $6,797 | None |
| Injection of additional new drug or substance into vein | 52 | $6,611 | $21 |
| Administration of chemotherapy into vein, each additional hour | 29 | $6,519 | $26 |
| Injection of drug or substance into vein | 50 | $5,575 | $53 |
| Injection, zoledronic acid, 1 mg | 19 | $5,312 | None |
| Biopsy of bone marrow | 23 | $3,808 | $159 |
| Irrigation of implanted venous access drug delivery device | 35 | $2,954 | $22 |
| Infusion into a vein for hydration, each additional hour | 42 | $2,579 | $14 |
| Injection, fluorouracil, 500 mg | 15 | $2,097 | None |
| Injection, carboplatin, 50 mg | 18 | $1,918 | None |
| Aspiration of bone marrow sample for diagnosis | 23 | $1,876 | $78 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,595 | $31 |
| Injection, paclitaxel, 1 mg | 11 | $1,489 | None |
| Insertion of needle into vein for collection of blood sample | 274 | $1,120 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 32 | $708 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 66 | $475 | None |
| Infusion, normal saline solution , 1000 cc | 57 | $444 | None |
| Injection, ranitidine hydrochloride, 25 mg | 37 | $278 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 57 | $160 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 26 | $58 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 16 | $48 | None |
| Unclassified drugs | 14 | $14 | None |
2015: 45 services
| Injection, pegfilgrastim, 6 mg | 26 | $362,620 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 31 | $277,164 | None |
| Return visit (30+ min) | 655 | $274,370 | $91 |
| Injection, denosumab, 1 mg | 53 | $211,957 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 27 | $85,537 | None |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 27 | $81,618 | None |
| Administration of chemotherapy into vein, 1 hour or less | 65 | $71,471 | $130 |
| Short return visit (20+ min) | 218 | $68,782 | $65 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 72 | $61,449 | $1 |
| Injection, palonosetron hcl, 25 mcg | 43 | $46,263 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 609 | $39,004 | $10 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 141 | $36,579 | $89 |
| Long return visit (40+ min) | 160 | $34,221 | $125 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 63 | $30,298 | $72 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 73 | $27,782 | $29 |
| New patient visit (60+ min) | 146 | $25,742 | $176 |
| Injection of drug or substance under skin or into muscle | 119 | $25,199 | $24 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $22,225 | $174 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 109 | $21,823 | $67 |
| Infusion into a vein for hydration, 31-60 minutes | 63 | $16,607 | $54 |
| Injection, zoledronic acid, 1 mg | 22 | $11,185 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 66 | $10,296 | $62 |
| Administration of additional new drug or substance into vein, 1 hour or less | 25 | $8,468 | $60 |
| Administration of chemotherapy into vein using push technique | 14 | $7,844 | $107 |
| Administration of chemotherapy into vein, each additional hour | 32 | $6,113 | $27 |
| Injection of additional new drug or substance into vein | 51 | $5,717 | $21 |
| Injection of drug or substance into vein | 47 | $5,543 | $55 |
| Administration of additional new drug or substance into vein using push technique | 18 | $5,352 | $59 |
| Infusion into a vein for hydration, each additional hour | 58 | $4,696 | $14 |
| Irrigation of implanted venous access drug delivery device | 36 | $3,586 | $23 |
| Biopsy of bone marrow | 14 | $2,222 | $159 |
| Injection, carboplatin, 50 mg | 20 | $1,859 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $1,801 | $19 |
| Injection, fluorouracil, 500 mg | 14 | $1,501 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $1,331 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 14 | $1,245 | $18 |
| Aspiration of bone marrow sample for diagnosis | 14 | $1,094 | $78 |
| Insertion of needle into vein for collection of blood sample | 164 | $635 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 35 | $605 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 62 | $559 | None |
| Infusion, normal saline solution , 1000 cc | 66 | $501 | None |
| Injection, ranitidine hydrochloride, 25 mg | 44 | $396 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 58 | $171 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 23 | $32 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 26 | $29 | None |
2014: 55 services
| Injection, pegfilgrastim, 6 mg | 33 | $426,052 | None |
| Injection, pemetrexed, not otherwise specified, 10 mg | 14 | $320,736 | None |
| Return visit (30+ min) | 635 | $272,656 | $92 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 33 | $183,568 | None |
| Injection, denosumab, 1 mg | 41 | $166,354 | None |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 21 | $94,197 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 21 | $64,695 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 69 | $60,134 | $1 |
| Administration of chemotherapy into vein, 1 hour or less | 66 | $57,524 | $127 |
| Short return visit (20+ min) | 234 | $49,578 | $63 |
| Injection, palonosetron hcl, 25 mcg | 50 | $42,250 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 156 | $37,606 | $89 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 569 | $35,755 | $10 |
| Long return visit (40+ min) | 173 | $35,560 | $123 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 139 | $27,490 | $173 |
| New patient visit (60+ min) | 154 | $27,095 | $176 |
| Injection, zoledronic acid, 1 mg | 19 | $23,246 | None |
| Injection, docetaxel, 1 mg | 12 | $21,515 | None |
| Injection of drug or substance under skin or into muscle | 123 | $21,345 | $23 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 80 | $19,929 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 82 | $17,746 | $65 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $14,682 | $71 |
| Administration of additional new drug or substance into vein using push technique | 24 | $11,136 | $58 |
| Injection of drug or substance into vein | 74 | $10,578 | $53 |
| Administration of additional new drug or substance into vein, 1 hour or less | 36 | $10,489 | $59 |
| Infusion into a vein for hydration, 31-60 minutes | 39 | $9,983 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 61 | $9,655 | $62 |
| Injection of additional new drug or substance into vein | 63 | $9,610 | $21 |
| Administration of chemotherapy into vein using push technique | 33 | $7,974 | $105 |
| Blood test, comprehensive group of blood chemicals | 330 | $7,337 | $14 |
| Administration of chemotherapy into vein, each additional hour | 29 | $5,491 | $26 |
| Irrigation of implanted venous access drug delivery device | 35 | $3,807 | $23 |
| Infusion into a vein for hydration, each additional hour | 38 | $2,963 | $14 |
| Aspiration of bone marrow sample for diagnosis | 25 | $2,802 | $112 |
| Biopsy of bone marrow | 21 | $2,224 | $106 |
| Injection, carboplatin, 50 mg | 22 | $1,885 | None |
| Ferritin (blood protein) level | 85 | $1,877 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $1,578 | $17 |
| Carcinoembryonic antigen (cea) protein level | 31 | $1,014 | $25 |
| Insertion of needle into vein for collection of blood sample | 206 | $773 | $3 |
| Cyanocobalamin (vitamin b-12) level | 33 | $766 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $626 | $19 |
| Folic acid level, serum | 29 | $609 | $20 |
| Injection, dexamethasone sodium phosphate, 1 mg | 65 | $469 | None |
| Injection, ranitidine hydrochloride, 25 mg | 46 | $321 | None |
| Lactate dehydrogenase (enzyme) level | 46 | $313 | $5 |
| Infusion, normal saline solution , 1000 cc | 61 | $282 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 26 | $232 | None |
| Iron level | 20 | $173 | $9 |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 15 | $169 | $11 |
| Injection, diphenhydramine hcl, up to 50 mg | 61 | $153 | None |
| Iron binding capacity | 12 | $112 | $9 |
| Injection, ondansetron hydrochloride, per 1 mg | 23 | $50 | None |
| Stool analysis for blood to screen for colon tumors | 11 | $48 | $4 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 26 | $17 | None |
2013: 59 services
| Injection, pemetrexed, not otherwise specified, 10 mg | 14 | $321,202 | None |
| Injection, pegfilgrastim, 6 mg | 31 | $304,229 | None |
| Return visit (30+ min) | 494 | $198,080 | $89 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 42 | $186,822 | None |
| Injection, denosumab, 1 mg | 28 | $97,704 | None |
| Injection, filgrastim (g-csf), 480 mcg | 21 | $55,184 | None |
| Administration of chemotherapy into vein, 1 hour or less | 65 | $51,258 | $137 |
| Long return visit (40+ min) | 207 | $40,514 | $120 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 46 | $34,628 | $1 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 134 | $34,560 | $85 |
| Injection, zoledronic acid (zometa), 1 mg | 16 | $34,226 | None |
| Short return visit (20+ min) | 182 | $32,899 | $64 |
| Zoldedronic acid 1mg | 24 | $32,205 | $135 |
| Injection, palonosetron hcl, 25 mcg | 42 | $30,460 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 448 | $26,866 | $11 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 12 | $25,883 | None |
| New patient visit (60+ min) | 150 | $25,784 | $172 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 103 | $19,678 | $164 |
| Injection of drug or substance under skin or into muscle | 125 | $17,974 | $24 |
| Administration of chemotherapy into vein using push technique | 55 | $16,434 | $107 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 89 | $13,821 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 64 | $12,395 | $71 |
| Blood test, comprehensive group of blood chemicals | 286 | $11,425 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 63 | $10,242 | $60 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $9,563 | $72 |
| Administration of additional new drug or substance into vein, 1 hour or less | 30 | $7,506 | $68 |
| Administration of chemotherapy into vein, each additional hour | 40 | $6,759 | $29 |
| Infusion into a vein for hydration, 31-60 minutes | 30 | $6,591 | $55 |
| Biopsy of bone marrow | 31 | $4,682 | $151 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $3,425 | None |
| Aspiration of bone marrow sample for diagnosis | 33 | $3,283 | $97 |
| Ferritin (blood protein) level | 99 | $2,987 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 44 | $2,766 | $17 |
| Irrigation of implanted venous access drug delivery device | 32 | $2,649 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 28 | $2,498 | $20 |
| Administration of additional new drug or substance into vein using push technique | 14 | $2,486 | $59 |
| Cyanocobalamin (vitamin b-12) level | 85 | $2,142 | $20 |
| Folic acid level, serum | 77 | $1,771 | $20 |
| Carcinoembryonic antigen (cea) protein level | 36 | $1,622 | $26 |
| Injection, carboplatin, 50 mg | 19 | $1,505 | None |
| Injection of additional new drug or substance into vein | 32 | $1,410 | $21 |
| Psa (prostate specific antigen) measurement, total | 12 | $1,392 | $25 |
| Iron binding capacity | 90 | $1,288 | $9 |
| Infusion into a vein for hydration, each additional hour | 21 | $1,280 | $14 |
| Iron level | 90 | $1,200 | $9 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 44 | $873 | None |
| Injection of drug or substance into vein | 12 | $704 | $54 |
| Lactate dehydrogenase (enzyme) level | 48 | $626 | $7 |
| Infusion, normal saline solution , 1000 cc | 105 | $472 | None |
| Beta-2 microglobulin (protein) level | 16 | $458 | $22 |
| Insertion of needle into vein for collection of blood sample | 85 | $279 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 53 | $263 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 70 | $163 | None |
| Injection, ranitidine hydrochloride, 25 mg | 24 | $137 | None |
| Blood potassium level | 12 | $87 | $6 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 25 | $76 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 15 | $54 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 33 | $35 | None |
| Infusion, normal saline solution, 250 cc | 48 | $25 | None |
Medicaid work
$10,088 in 2024
Medicaid paid $10,088 for 233 billed services this clinician did in 2024, up to 28 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 202 | $8,762 |
| Long return visit (40+ min) | 31 | $1,326 |
| 2024 | 233 | 2 | 28 | $10,088 |
| 2023 | 278 | 2 | 25 | $8,120 |
| 2022 | 204 | 2 | 20 | $5,140 |
| 2021 | 260 | 2 | 19 | $6,543 |
| 2020 | 698 | 5 | 37 | $7,873 |
| 2019 | 842 | 5 | 32 | $11,096 |
| 2018 | 810 | 3 | 38 | $10,591 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 222 | $7,776 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 56 | $344 |
2022
| Return visit (30+ min) | 146 | $4,903 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 58 | $238 |
2021
| Return visit (30+ min) | 165 | $6,094 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 95 | $449 |
2020
| Return visit (30+ min) | 259 | $6,827 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 336 | $542 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 69 | $419 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 16 | $85 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 18 | $0 |
2019
| Return visit (30+ min) | 296 | $8,105 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 409 | $1,553 |
| Short return visit (20+ min) | 45 | $918 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 14 | $400 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 78 | $119 |
2018
| Return visit (30+ min) | 363 | $9,444 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 329 | $830 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 118 | $316 |
Drugs they prescribed that Part D paid
$214,810
Pharmacies billed $214,810 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 390) in 2024. At or below the middle of the specialty; the typical medical oncology clinician is at 6%.
306 generic and 84 brand-name prescriptions · $214,810 in drug cost · 20 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xarelto | 33 | $28,719 | $870 |
| Eliquis | 26 | $14,893 | $573 |
| Letrozole | 46 | $1,422 | $31 |
| Amikacin Sulfate | 16 | $1,253 | $78 |
| Bicalutamide | 20 | $368 | $18 |
See all 10 drugs
| Xarelto | 33 | $28,719 | $870 |
| Eliquis | 26 | $14,893 | $573 |
| Letrozole | 46 | $1,422 | $31 |
| Amikacin Sulfate | 16 | $1,253 | $78 |
| Bicalutamide | 20 | $368 | $18 |
| Tamoxifen Citrate | 16 | $291 | $18 |
| Alendronate | 30 | $245 | $8 |
| Allopurinol | 27 | $160 | $6 |
| Prednisone | 38 | $93 | $2 |
| Tamsulosin | 11 | $60 | $5 |
Year by year
| 2024 | 390 | 128 | 0% (0) | 22% | $214,810 |
| 2023 | 346 | 118 | 0% (0) | None | $199,309 |
| 2022 | 295 | 100 | 0% (0) | 48% | $910,239 |
| 2021 | 371 | 123 | None | 33% | $1,256,443 |
| 2020 | 484 | 146 | None | 25% | $826,931 |
| 2019 | 773 | 181 | 2% (14) | 26% | $1,637,757 |
| 2018 | 1,113 | 217 | 5% (51) | 24% | $1,944,105 |
| 2017 | 1,081 | 203 | 3% (35) | 26% | $1,865,108 |
| 2016 | 1,055 | 189 | 4% (38) | 24% | $1,654,882 |
| 2015 | 999 | 173 | None | 19% | $710,051 |
| 2014 | 1,022 | 188 | 5% (55) | 16% | $599,343 |
| 2013 | 1,004 | 177 | 4% (41) | None | $592,610 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Lynparza | 11 | $95,282 | $8,662 |
| Xarelto | 32 | $27,177 | $849 |
| Eliquis | 21 | $13,978 | $666 |
| Letrozole | 48 | $1,508 | $31 |
| Bicalutamide | 13 | $299 | $23 |
| Prednisone | 52 | $238 | $5 |
| Hydroxyurea | 17 | $235 | $14 |
| Warfarin | 13 | $195 | $15 |
| Alendronate | 12 | $169 | $14 |
| Tamsulosin | 17 | $154 | $9 |
| Allopurinol | 38 | $120 | $3 |
2022: 6 drugs
| Tagrisso | 12 | $200,159 | $16,680 |
| Xarelto | 53 | $38,179 | $720 |
| Eliquis | 27 | $16,461 | $610 |
| Letrozole | 39 | $1,236 | $32 |
| Hydroxyurea | 13 | $196 | $15 |
| Allopurinol | 18 | $93 | $5 |
2021: 10 drugs
| Xtandi | 22 | $291,398 | $13,245 |
| Tagrisso | 11 | $181,363 | $16,488 |
| Abiraterone Acetate | 19 | $156,823 | $8,254 |
| Xarelto | 30 | $19,847 | $662 |
| Letrozole | 37 | $1,293 | $35 |
| Hydroxyurea | 22 | $721 | $33 |
| Dexamethasone | 18 | $602 | $33 |
| Tamoxifen Citrate | 11 | $431 | $39 |
| Prednisone | 32 | $275 | $9 |
| Allopurinol | 19 | $127 | $7 |
2020: 12 drugs
| Lynparza | 12 | $175,870 | $14,656 |
| Ninlaro | 11 | $111,256 | $10,114 |
| Abiraterone Acetate | 12 | $61,374 | $5,114 |
| Xarelto | 44 | $30,455 | $692 |
| Letrozole | 49 | $1,582 | $32 |
| Hydroxyurea | 38 | $1,189 | $31 |
| Tamoxifen Citrate | 16 | $619 | $39 |
| Anastrozole | 18 | $400 | $22 |
| Prednisone | 43 | $352 | $8 |
| Dexamethasone | 20 | $328 | $16 |
| Acyclovir | 12 | $291 | $24 |
| Allopurinol | 21 | $155 | $7 |
2019: 21 drugs
| Revlimid | 37 | $455,338 | $12,306 |
| Imbruvica | 18 | $336,416 | $18,690 |
| Xtandi | 13 | $155,606 | $11,970 |
| Ninlaro | 11 | $110,410 | $10,037 |
| Xarelto | 47 | $33,176 | $706 |
| Eliquis | 23 | $12,745 | $554 |
| Exemestane | 13 | $3,365 | $259 |
| Letrozole | 126 | $2,744 | $22 |
| Hydroxyurea | 42 | $1,789 | $43 |
| Tamoxifen Citrate | 26 | $1,633 | $63 |
| Anastrozole | 43 | $1,203 | $28 |
| Ondansetron | 18 | $788 | $44 |
| Alendronate | 21 | $350 | $17 |
| Dexamethasone | 17 | $310 | $18 |
| Omeprazole | 34 | $290 | $9 |
| Pantoprazole | 18 | $237 | $13 |
| Allopurinol | 27 | $219 | $8 |
| Prednisone | 18 | $180 | $10 |
| Methotrexate | 13 | $176 | $14 |
| Acyclovir | 18 | $163 | $9 |
| Venlafaxine Hcl Er | 13 | $141 | $11 |
2018: 27 drugs
| Zytiga | 33 | $339,977 | $10,302 |
| Xtandi | 27 | $303,934 | $11,257 |
| Revlimid | 27 | $247,762 | $9,176 |
| Sutent | 13 | $191,009 | $14,693 |
| Promacta | 17 | $128,189 | $7,541 |
| Xarelto | 66 | $32,375 | $491 |
| Eliquis | 17 | $10,341 | $608 |
| Exemestane | 24 | $9,185 | $383 |
| Tamoxifen Citrate | 73 | $3,462 | $47 |
| Hydroxyurea | 61 | $3,058 | $50 |
| Letrozole | 165 | $2,321 | $14 |
| Megestrol Acetate | 13 | $1,339 | $103 |
| Anastrozole | 59 | $1,234 | $21 |
| Prednisone | 42 | $431 | $10 |
| Pantoprazole | 35 | $363 | $10 |
| Morphine Sulfate Er | 14 | $314 | $22 |
| Alendronate | 34 | $308 | $9 |
| Warfarin | 17 | $302 | $18 |
| Allopurinol | 27 | $268 | $10 |
| Dexamethasone | 12 | $266 | $22 |
| Hydrocodone-Acetaminophen | 15 | $246 | $16 |
| Ondansetron | 13 | $237 | $18 |
| Omeprazole | 30 | $216 | $7 |
| Escitalopram | 11 | $166 | $15 |
| Venlafaxine Hcl Er | 14 | $161 | $12 |
| Mirtazapine | 16 | $114 | $7 |
| Lorazepam | 29 | $108 | $4 |
2017: 25 drugs
| Xtandi | 55 | $554,274 | $10,078 |
| Revlimid | 43 | $506,654 | $11,783 |
| Ninlaro | 15 | $147,645 | $9,843 |
| Promacta | 22 | $103,627 | $4,710 |
| Xarelto | 56 | $22,477 | $401 |
| Creon | 12 | $11,959 | $997 |
| Hydroxyurea | 62 | $3,555 | $57 |
| Tamoxifen Citrate | 52 | $2,839 | $55 |
| Letrozole | 164 | $1,808 | $11 |
| Raloxifene | 22 | $1,612 | $73 |
| Anastrozole | 75 | $1,055 | $14 |
| Bicalutamide | 17 | $382 | $22 |
| Dexamethasone | 18 | $365 | $20 |
| Acyclovir | 23 | $318 | $14 |
| Prednisone | 20 | $265 | $13 |
| Omeprazole | 42 | $237 | $6 |
| Escitalopram | 20 | $190 | $9 |
| Hydrocodone-Acetaminophen | 13 | $173 | $13 |
| Ondansetron | 14 | $149 | $11 |
| Allopurinol | 15 | $149 | $10 |
| Levofloxacin | 24 | $143 | $6 |
| Pantoprazole | 17 | $125 | $7 |
| Tramadol | 13 | $64 | $5 |
| Lorazepam | 16 | $63 | $4 |
| Furosemide | 20 | $48 | $2 |
2016: 25 drugs
| Revlimid | 54 | $519,695 | $9,624 |
| Xtandi | 46 | $423,832 | $9,214 |
| Ninlaro | 23 | $205,047 | $8,915 |
| Promacta | 13 | $83,099 | $6,392 |
| Xarelto | 43 | $15,685 | $365 |
| Tamoxifen Citrate | 63 | $2,037 | $32 |
| Letrozole | 105 | $1,890 | $18 |
| Anastrozole | 122 | $1,765 | $14 |
| Hydroxyurea | 36 | $1,570 | $44 |
| Dexamethasone | 29 | $452 | $16 |
| Acyclovir | 22 | $351 | $16 |
| Lidocaine-Prilocaine | 13 | $347 | $27 |
| Ondansetron | 24 | $307 | $13 |
| Warfarin | 14 | $249 | $18 |
| Prednisone | 12 | $218 | $18 |
| Hydrocodone-Acetaminophen | 12 | $202 | $17 |
| Omeprazole | 44 | $200 | $5 |
| Escitalopram | 25 | $199 | $8 |
| Lorazepam | 48 | $197 | $4 |
| Venlafaxine Hcl Er | 15 | $139 | $9 |
| Prochlorperazine Maleate | 21 | $135 | $6 |
| Hydroxyzine | 15 | $133 | $9 |
| Mirtazapine | 16 | $87 | $5 |
| Citalopram Hbr | 11 | $44 | $4 |
| Gabapentin | 11 | $38 | $3 |
2015: 23 drugs
| Revlimid | 41 | $377,046 | $9,196 |
| Aranesp | 16 | $55,263 | $3,454 |
| Xarelto | 42 | $13,915 | $331 |
| Exemestane | 11 | $2,860 | $260 |
| Anastrozole | 175 | $2,637 | $15 |
| Tamoxifen Citrate | 72 | $1,866 | $26 |
| Hydroxyurea | 27 | $1,332 | $49 |
| Letrozole | 77 | $903 | $12 |
| Ondansetron | 41 | $834 | $20 |
| Allopurinol | 34 | $484 | $14 |
| Prednisone | 26 | $356 | $14 |
| Warfarin | 18 | $318 | $18 |
| Pantoprazole | 35 | $289 | $8 |
| Omeprazole | 31 | $278 | $9 |
| Lorazepam | 55 | $214 | $4 |
| Dexamethasone | 16 | $187 | $12 |
| Levofloxacin | 11 | $163 | $15 |
| Acyclovir | 11 | $157 | $14 |
| Venlafaxine Hcl Er | 16 | $143 | $9 |
| Escitalopram | 19 | $118 | $6 |
| Mirtazapine | 14 | $111 | $8 |
| Prochlorperazine Maleate | 13 | $93 | $7 |
| Furosemide | 16 | $58 | $4 |
2014: 23 drugs
| Revlimid | 12 | $127,597 | $10,633 |
| Xtandi | 15 | $124,585 | $8,306 |
| Xarelto | 38 | $12,135 | $319 |
| Anastrozole | 177 | $3,766 | $21 |
| Ondansetron | 48 | $1,650 | $34 |
| Hydroxyurea | 42 | $1,394 | $33 |
| Tamoxifen Citrate | 41 | $951 | $23 |
| Letrozole | 55 | $763 | $14 |
| Lidocaine-Prilocaine | 17 | $473 | $28 |
| Warfarin | 24 | $382 | $16 |
| Hydrocodone-Acetaminophen | 14 | $354 | $25 |
| Omeprazole | 33 | $349 | $11 |
| Prednisone | 26 | $331 | $13 |
| Pantoprazole | 38 | $273 | $7 |
| Lorazepam | 56 | $243 | $4 |
| Potassium Chloride | 12 | $227 | $19 |
| Escitalopram | 23 | $214 | $9 |
| Prochlorperazine Maleate | 27 | $205 | $8 |
| Dexamethasone | 26 | $179 | $7 |
| Levofloxacin | 11 | $118 | $11 |
| Tramadol | 13 | $74 | $6 |
| Allopurinol | 13 | $71 | $5 |
| Furosemide | 11 | $24 | $2 |
2013: 26 drugs
| Revlimid | 28 | $253,039 | $9,037 |
| Tarceva | 23 | $112,437 | $4,889 |
| Enoxaparin | 15 | $17,170 | $1,145 |
| Anastrozole | 143 | $4,005 | $28 |
| Xarelto | 14 | $3,810 | $272 |
| Letrozole | 57 | $1,712 | $30 |
| Hydroxyurea | 30 | $1,275 | $43 |
| Omeprazole | 48 | $726 | $15 |
| Warfarin | 44 | $726 | $16 |
| Tamoxifen Citrate | 47 | $668 | $14 |
| Ondansetron | 26 | $582 | $22 |
| Acyclovir | 16 | $566 | $35 |
| Pantoprazole | 23 | $474 | $21 |
| Levofloxacin | 21 | $398 | $19 |
| Lidocaine-Prilocaine | 12 | $301 | $25 |
| Prochlorperazine Maleate | 40 | $262 | $7 |
| Mirtazapine | 19 | $224 | $12 |
| Hydrocodone-Acetaminophen | 14 | $196 | $14 |
| Lorazepam | 37 | $184 | $5 |
| Prednisone | 23 | $154 | $7 |
| Dexamethasone | 23 | $145 | $6 |
| Potassium Chloride | 11 | $139 | $13 |
| Folic Acid | 22 | $124 | $6 |
| Lidocaine Hcl Viscous | 13 | $117 | $9 |
| Allopurinol | 12 | $51 | $4 |
| Furosemide | 11 | $31 | $3 |
Money from drug and device companies
$8,856 in 2025
| 2025 | 7 | 11 | $7,987 | $8,856 |
| 2024 | 8 | 16 | $16,592 | $18,664 |
| 2023 | 12 | 26 | $7,741 | $9,398 |
| 2022 | 12 | 28 | $8,903 | $10,754 |
| 2021 | 4 | 32 | $20,125 | $20,672 |
| 2020 | 4 | 37 | $33,300 | $37,400 |
| 2019 | 5 | 54 | $46,365 | $56,468 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Keytruda | $5,476 | 4 payments
|
| Rigel Pharmaceuticals | Tavalisse | $3,217 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $56 | 2 payments
|
| Abbvie | Imbruvica | $28 | 1 payment
|
| Gilead Sciences | Trodelvy | $27 | 1 payment
|
| Daiichi Sankyo | Enhertu | $27 | 1 payment
|
See all 11 published payments
| Abbvie | Meals · 2025-12-04 | Imbruvica | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-25 | Iclusig | $30 |
| Gilead Sciences | Meals · 2025-10-23 | Trodelvy | $27 |
| Merck Sharp & Dohme | Travel · 2025-08-27 | Keytruda | $75 |
| Merck Sharp & Dohme | Paid to speak or teach · 2025-08-27 | Keytruda | $4,770 |
| Merck Sharp & Dohme | Travel · 2025-08-21 | Keytruda | $569 |
| Merck Sharp & Dohme | Meals · 2025-08-21 | Keytruda | $62 |
| Teleflex | Meals · 2025-06-25 | Arrow | $25 |
| Rigel Pharmaceuticals | Consulting · 2025-05-23 | Tavalisse | $3,217 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-22 | Iclusig | $26 |
| Daiichi Sankyo | Meals · 2025-05-06 | Enhertu | $27 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $18,664
| Rigel Pharmaceuticals | Rezlidhia | $15,547 | 6 payments
|
| Olympus America | Evis Exera III Colonovideoscope | $1,639 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $1,302 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $59 | 2 payments
|
| SpringWorks Therapeutics | Ogsiveo | $47 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $26 | 1 payment
|
| Pfizer | Inlyta | $25 | 1 payment
|
| Gilead Sciences | None | $19 | 1 payment
|
2023: $9,398
| Rigel Pharmaceuticals | Rezlidhia | $8,986 | 8 payments
|
| Pfizer | Inlyta | $76 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $72 | 3 payments
|
| Amgen | Evenity | $51 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $46 | 2 payments
|
| Daiichi Sankyo | Injectafer | $39 | 2 payments
|
| Gilead Sciences | None | $23 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $23 | 1 payment
|
| Stemline Therapeutics | Orserdu | $23 | 1 payment
|
| Celgene | Pomalyst | $23 | 1 payment
|
| Sobi | Doptelet | $20 | 1 payment
|
| Coherus Biosciences | Udenyca | $16 | 1 payment
|
2022: $10,754
| Rigel Pharmaceuticals | Tavalisse | $10,224 | 13 payments
|
| Ethicon | N/A | $159 | 1 payment
|
| Abbvie | Venclexta | $100 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $56 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | None | $47 | 2 payments
|
| GlaxoSmithKline | Blenrep | $35 | 1 payment
|
| Daiichi Sankyo | Injectafer | $30 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $26 | 2 payments
|
| Coherus Biosciences | Udenyca | $25 | 2 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $23 | 1 payment
|
| Novartis Pharmaceuticals | Mekinist | $17 | 1 payment
|
| Janssen Pharmaceuticals | None | $12 | 1 payment
|
2021: $20,672
| Rigel Pharmaceuticals | Tavalisse | $20,304 | 16 payments
|
| Pfizer | Inlyta | $286 | 13 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $67 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $15 | 1 payment
|
2020: $37,400
| Rigel Pharmaceuticals | Tavalisse | $31,298 | 28 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $5,962 | 5 payments
|
| IntrinsiQ Specialty Solutions | None | $100 | 1 payment
|
| Pfizer | Inlyta | $40 | 3 payments
|
2019: $56,468
| Merck Sharp & Dohme | Keytruda | $34,523 | 30 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $12,898 | 11 payments
|
| AMAG Pharmaceuticals | Feraheme | $4,951 | 4 payments
|
| Rigel Pharmaceuticals | Tavalisse | $4,083 | 8 payments
|
| Pfizer | Braftovi | $13 | 1 payment
|
Professional record
- NPI
- 1881812519
- Licence
- CA A86449California A86449: Current · expires 2028-03-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 5725 W Las Positas Blvd # 100a, Pleasanton, CA, 94588
- NPI first listed
- 2007-04-20
- NPI last updated
- 2024-08-20
- NPI record certified
- 2024-08-20
This is when the NPI record was last certified, not a medical board exam.